Bal Pharma's

Divis Labs on expansion mode, to invest Rs 15 billion

Divis Laboratories has decided to spend Rs 15 billion to expand existing facilities over the next 15 months.

The maker of active pharmaceutical ingredients (APIs) and drug intermediates said it would be investing Rs 6 billion each on its Unit-2 at the Vizag SEZ in Andhra and Unit-1 of its Nalgonda SEZ in Telangana.

Another Rs 3 billion will be invested for de-bottlenecking at Vizag. All the work is expected to be complete by end-December 2019. At present, the company operates four multipurpose manufacturing facilities, from these two sites.

Divis said the investment was to cater for the rising opportunities in generic and big pharmaceutical businesses. The company makes key ingredients for the final products of formulations companies.

Its portfolio has two broad segments- Generic APIs & nutraceuticals and custom synthesis of APIs, intermediates & speciality ingredients for innovator pharma giants.

Image Credit : cdn.telanganatoday.com